SCHEMBL4740457

SCHEMBL4740457

COc1ccc(-c2ccc(NC(=O)Nc3cc(C)cc(C)c3)cc2)c2c(N)onc12

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 18/20 0.60
KDR P35968 17/20 0.60
FLT1 P17948 10/20 0.60
FLT4 P35916 7/20 0.60
BLK P51451 7/20 0.60
LCK P06239 6/20 0.60
LYN P07948 6/20 0.60
FYN P06241 5/20 0.60
AURKA O14965 5/20 0.60
ROCK2 O75116 5/20 0.60
FGFR1 P11362 5/20 0.60
RPS6KB1 P23443 5/20 0.60
RPS6KA3 P51812 5/20 0.60
ROCK1 Q13464 5/20 0.60
AURKB Q96GD4 5/20 0.60
SRC P12931 4/20 0.60
RPS6KA5 O75582 4/20 0.60
NTRK1 P04629 4/20 0.60
RET P07949 4/20 0.60
FER P16591 4/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1384165 0.93 FLT3 (0.59) FLT3KDRFLT1FLT4BLK
SCHEMBL4735281 0.91 KDR (0.65) FLT3KDRFLT1FLT4BLK
SCHEMBL1379853 0.89 KDR (0.61) FLT3KDRFLT1FLT4BLK
SCHEMBL4738212 0.89 KDR (0.75) FLT3KDRFLT1FLT4BLK
SCHEMBL1380283 0.86 KDR (0.77) FLT3KDRFLT1FLT4BLK
SCHEMBL4736487 0.86 KDR (0.65) FLT3KDRFLT1FLT4BLK
SCHEMBL3394108 0.86 KDR (0.78) FLT3KDRFLT1FLT4BLK
SCHEMBL424288 0.86 KDR (0.80) FLT3KDRFLT1FLT4BLK
SCHEMBL4736893 0.86 KDR (0.55) FLT3KDRFLT1FLT4BLK
SCHEMBL4738551 0.85 KDR (0.66) FLT3KDRFLT1FLT4BLK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008080110-A1 METHODS FOR TREATING MACULAR EDEMA AND PATHOLOGIC OCULAR ANGIOGENESIS USING A NEUROPROTECTIVE AGENT AND A RECEPTOR TYROSINE KINASE INHIBITOR ALCON, INC. (CH) 2008-07-03 WO claimed
EP-1850839-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON INC. (CH) 2007-11-07 EP claimed
WO-2006091801-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON, INC. (CH) 2006-08-31 WO claimed
WO-2008080110-A1 METHODS FOR TREATING MACULAR EDEMA AND PATHOLOGIC OCULAR ANGIOGENESIS USING A NEUROPROTECTIVE AGENT AND A RECEPTOR TYROSINE KINASE INHIBITOR ALCON, INC. (CH) 2008-07-03 WO disclosed